Estuary Biotherapeutics, a biotech developing gene therapies for kidney disease, is emerging from stealth with $103 million, the company announced Friday.
Why it matters: Estuary aims to tackle the root cause of autosomal dominant polycystic kidney disease (ADPKD), which has just one FDA-approved treatment to slow its progression.
